Cargando…

A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India

Objective  Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the di...

Descripción completa

Detalles Bibliográficos
Autores principales: Somal, Puneet Kaur, Sancheti, Sankalp, Sharma, Aishwarya, Sali, Akash Pramod, Chaudhary, Debashish, Goel, Alok, Dora, Tapas Kumar, Brar, Rahat, Gulia, Ashish, Divatia, Jigeeshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635761/
https://www.ncbi.nlm.nih.gov/pubmed/37969672
http://dx.doi.org/10.1055/s-0043-1761942
_version_ 1785146358002352128
author Somal, Puneet Kaur
Sancheti, Sankalp
Sharma, Aishwarya
Sali, Akash Pramod
Chaudhary, Debashish
Goel, Alok
Dora, Tapas Kumar
Brar, Rahat
Gulia, Ashish
Divatia, Jigeeshu
author_facet Somal, Puneet Kaur
Sancheti, Sankalp
Sharma, Aishwarya
Sali, Akash Pramod
Chaudhary, Debashish
Goel, Alok
Dora, Tapas Kumar
Brar, Rahat
Gulia, Ashish
Divatia, Jigeeshu
author_sort Somal, Puneet Kaur
collection PubMed
description Objective  Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the different molecular subtypes of invasive breast carcinoma and study the clinicopathological parameters in a tertiary care cancer center in rural North India. Materials and Methods  All female patients diagnosed with invasive breast cancer and registered between January 1, 2015, and December 31, 2020, were included. Patients with bilateral cancer, missing information on HER2/ER/PR receptor status, absence of reflex FISH testing after an equivocal score on Her 2 IHC were excluded. The tumors were classified into different molecular subtypes based on IHC expression as follows-luminal A-like (ER- and PR-positive, Her2-negative, Ki67 < 20%), luminal B-like Her2-negative (ER-positive, Her2-negative and any one of the following Ki67% ≥ 20% or PR-negative/low, luminal B-like Her2-positive (ER- and HER2-positive, any Ki67, any PR), Her2-positive (ER- and PR-negative, Her2-positive) and TNBC (ER, PR, Her2-negative). Chi square test was used to compare the clinicopathological parameters between these subtypes. Results  A total of 1,625 cases were included. Luminal B-like subtype was the most common (41.72%). The proportion of each subtype was luminal A (15.69%), luminal B Her2-negative (23.93%), luminal B Her2-positive (17.78%), Her2-positive (15.26%), TNBC (27.32%). Majority of the tumors were Grade 3 (75.81%). Nodal metastases were present in 59%. On subanalysis of the luminal type tumors without Her2 expression (luminal A-like and luminal B-like (Her2-negative), luminal A-like tumors presented significantly with a lower grade ( p  < 0.001) and more frequent node-negative disease in comparison to luminal B-like (Her2-negative) tumors. In comparison to other subtypes, TNBC tumors were more frequently seen in the premenopausal age group ( p  < 0.001) and presented with node-negative disease ( p  < 0.001). Conclusion  This is one of the largest studies that enumerates the prevalence of various molecular subtypes of breast cancer in North India. Luminal B-like tumors were the most common followed by TNBC. TNBC tumors presented more commonly in premenopausal age group and with node negative disease in comparison to other subtypes.
format Online
Article
Text
id pubmed-10635761
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-106357612023-11-15 A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India Somal, Puneet Kaur Sancheti, Sankalp Sharma, Aishwarya Sali, Akash Pramod Chaudhary, Debashish Goel, Alok Dora, Tapas Kumar Brar, Rahat Gulia, Ashish Divatia, Jigeeshu South Asian J Cancer Objective  Classification of breast cancer into different molecular subtypes has important prognostic and therapeutic implications. The immunohistochemistry surrogate classification has been advocated for this purpose. The primary objective of the present study was to assess the prevalence of the different molecular subtypes of invasive breast carcinoma and study the clinicopathological parameters in a tertiary care cancer center in rural North India. Materials and Methods  All female patients diagnosed with invasive breast cancer and registered between January 1, 2015, and December 31, 2020, were included. Patients with bilateral cancer, missing information on HER2/ER/PR receptor status, absence of reflex FISH testing after an equivocal score on Her 2 IHC were excluded. The tumors were classified into different molecular subtypes based on IHC expression as follows-luminal A-like (ER- and PR-positive, Her2-negative, Ki67 < 20%), luminal B-like Her2-negative (ER-positive, Her2-negative and any one of the following Ki67% ≥ 20% or PR-negative/low, luminal B-like Her2-positive (ER- and HER2-positive, any Ki67, any PR), Her2-positive (ER- and PR-negative, Her2-positive) and TNBC (ER, PR, Her2-negative). Chi square test was used to compare the clinicopathological parameters between these subtypes. Results  A total of 1,625 cases were included. Luminal B-like subtype was the most common (41.72%). The proportion of each subtype was luminal A (15.69%), luminal B Her2-negative (23.93%), luminal B Her2-positive (17.78%), Her2-positive (15.26%), TNBC (27.32%). Majority of the tumors were Grade 3 (75.81%). Nodal metastases were present in 59%. On subanalysis of the luminal type tumors without Her2 expression (luminal A-like and luminal B-like (Her2-negative), luminal A-like tumors presented significantly with a lower grade ( p  < 0.001) and more frequent node-negative disease in comparison to luminal B-like (Her2-negative) tumors. In comparison to other subtypes, TNBC tumors were more frequently seen in the premenopausal age group ( p  < 0.001) and presented with node-negative disease ( p  < 0.001). Conclusion  This is one of the largest studies that enumerates the prevalence of various molecular subtypes of breast cancer in North India. Luminal B-like tumors were the most common followed by TNBC. TNBC tumors presented more commonly in premenopausal age group and with node negative disease in comparison to other subtypes. Thieme Medical and Scientific Publishers Pvt. Ltd. 2023-03-09 /pmc/articles/PMC10635761/ /pubmed/37969672 http://dx.doi.org/10.1055/s-0043-1761942 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Somal, Puneet Kaur
Sancheti, Sankalp
Sharma, Aishwarya
Sali, Akash Pramod
Chaudhary, Debashish
Goel, Alok
Dora, Tapas Kumar
Brar, Rahat
Gulia, Ashish
Divatia, Jigeeshu
A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
title A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
title_full A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
title_fullStr A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
title_full_unstemmed A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
title_short A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India
title_sort clinicopathological analysis of molecular subtypes of breast cancer using immunohistochemical surrogates: a 6-year institutional experience from a tertiary cancer center in north india
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635761/
https://www.ncbi.nlm.nih.gov/pubmed/37969672
http://dx.doi.org/10.1055/s-0043-1761942
work_keys_str_mv AT somalpuneetkaur aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT sanchetisankalp aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT sharmaaishwarya aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT saliakashpramod aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT chaudharydebashish aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT goelalok aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT doratapaskumar aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT brarrahat aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT guliaashish aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT divatiajigeeshu aclinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT somalpuneetkaur clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT sanchetisankalp clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT sharmaaishwarya clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT saliakashpramod clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT chaudharydebashish clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT goelalok clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT doratapaskumar clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT brarrahat clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT guliaashish clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia
AT divatiajigeeshu clinicopathologicalanalysisofmolecularsubtypesofbreastcancerusingimmunohistochemicalsurrogatesa6yearinstitutionalexperiencefromatertiarycancercenterinnorthindia